Aclaris Therapeutics Inc. priced an underwritten public offering of 3,260,000 common shares at $23.02 apiece, for expected gross proceeds of $75 million.
The company also granted underwriters a 30-day option to buy up to an additional 489,000 common shares at the public offering price.
The offering is expected to close on or around Aug. 16, subject to customary closing conditions.
Aclaris expects net proceeds of $70.3 million, after underwriting discounts, commissions and estimated offering expenses.
Jefferies LLC and Leerink Partners LLC are acting as joint book-running managers for the offering, with William Blair & Co. LLC, Guggenheim Securities LLC and JMP Securities LLC as co-managers.